The DOI matches its Crossref record.
Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen
Open accessAbstract
In a few patients with chronic sarcoidosis, prolonged, unacceptably high doses of corticosteroids are required to achieve symptomatic relief. In these cases, a corticosteroid-sparing drug might be administered to allow long-term treatment without the adverse effects of corticosteroids. This study examines azathioprine as a prednisolone-sparing treatment. In an open study, the course of 11 patients with chronic sarcoidosis was analysed. In an induction phase, 2 mg azathioprine x kg body weight (BW)(-1) x day(-1) in combination with 0.6-0.8 mg prednisolone x kg BW(-1) x day(-1) were administered with prednisolone being reduced to 0.1 mg x kg BW(-1) x day(-1) within 2-3 months. This was followed by a 21-22-month maintenance phase with 2 mg azathioprine x kg BW(-1) x day(-1) and 0.1 mg prednisolone x kg BW(-1) day(-1). Clinical parameters and immunological findings of bronchoalveolar lavage (BAL) were analysed. All patients had significant symptomatic relief and improvements or resolutions of physiological, serological and radiographic findings without suffering from serious adverse effects. Nine of 11 patients completed therapy after 19-26 months, and 2/11 patients terminated therapy after 8 and 12 months, respectively. Eight patients had remissions lasting 4-73 months. Three relapses occurred after 8, 18, and 22 months. During the induction phase, BAL cell composition changed and their activity in terms of cytokine release was suppressed. This preliminary study suggests that azathioprine may be effective as a corticosteroid-sparing agent in long-term therapy of sarcoidosis, but a much larger study is necessary to give the definitive answer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Valeyre, D., Prasse, A., Nunes, H., Uzunhan, Y., Brillet, P.-Y., & Müller-Quernheim, J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60680-7 · Cited by 1,087
Self-citationInterstitial lung disease guideline
Wells, A. U., Hirani, N., & on behalf of the BTS Interstitial Lung Disease Guideline Group, A. S. O. T. B. T. S. S. O. C. C. (2008) · Thorax · doi:10.1136/thx.2008.101691 · Cited by 866
Baughman, R. P., Lower, E. E., & du Bois, R. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12888-7 · Cited by 657
ERS clinical practice guidelines on treatment of sarcoidosis
Baughman, R. P., Valeyre, D., Korsten, P., Mathioudakis, A. G., Wuyts, W. A., Wells, A., Rottoli, P., Nunes, H., Lower, E. E., Judson, M. A., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04079-2020 · Cited by 629
Birnie, D. H., Nery, P. B., Ha, A. C., & Beanlands, R. S. B. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.605 · Cited by 569
Metadata
- Authors
- Muller-Quernheim, J., Kienast, K., Held, M., Pfeifer, S., & Costabel, U.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 1999-11-01
- Volume
- 14
- Issue
- 5
- Pages
- 1117-1122
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2124102081
- Cited by
- 244
- References
- 0
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. https://app.cochat.ai/papers/10.1183/09031936.99.14511179
- The paper
- Muller-Quernheim, J., Kienast, K., Held, M., Pfeifer, S., & Costabel, U. (1999). Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. European Respiratory Journal. https://doi.org/10.1183/09031936.99.14511179
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.